サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：予測診断の世界市場-2023-2030
市場調査レポート
商品コード
1176560

予測診断の世界市場-2023-2030

Global Predictive Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
予測診断の世界市場-2023-2030
出版日: 2022年12月26日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

予測診断の世界市場は、予測期間（2023-2030年）に著しく成長すると予測されています。

予測診断では、カスタマイズされたデータと一連の診断装置を用いて、正確でリアルタイムの洞察を提供し、潜在的な問題を特定します。分子技術革新、ゲノミクス応用、迅速な研究開発プロセスを統合することで、予測診断は業務にインパクトを与え、測定可能な進歩をもたらすことができます。

市場力学

世界の予知診断市場は、技術の進歩、研究開発における予知診断の採用拡大、生活習慣病の増加、健康志向の高まりによって牽引されています。

ヘルスケアにおける予測診断のメリットの増加が市場成長の原動力

診断分野における技術の進歩は、予測期間中の市場を牽引します。フィリップスのレポート「2020年6月」によると、ヘルスケアにおける予測分析は、集中治療室や一般病棟における患者の変性の早期兆候を検出し、住居でリスクのある患者を認識して病院の再入院を防止し、医療機器の回避可能なダウンタイムを防止するのに役立ちます。予測診断では、病院の電子カルテ、転倒検知用ペンダント、医療通報サービスの利用履歴など、複数のソースからのデータを組み合わせて、今後30日以内に救急搬送の危険性がある高齢者を特定することができます。予測診断により、ヘルスケアプロバイダーは、転倒やその他の医療合併症が起こる前に高齢者に手を差し伸べることができ、不必要な病院への再入院を防ぎ、搬送、急性期治療、リハビリテーションのコストを削減することができます。

また、市場参加者は、製品投入や協業などの市場戦略を適用し、事業拡大を図っています。例えば、2021年10月には、体外診断に注力するフランスの多国籍バイオテクノロジー企業であるbioMerieux社が、食品の安全性と食品の品質に関する同社の新しい提案であるpredictive Diagnosticsを発売しています。また、2022年9月には、QIAGENと、遺伝的に定義された神経疾患および免疫疾患に対する精密医薬品の設計に注力するバイオテクノロジー組織Neuron23 Inc.が、Neuron23のパーキンソン病に対する脳浸透性ロイシンリッチリピートキナーゼ（LRRK2）阻害剤のコンパニオン診断薬を創出することに合意しました。本契約において、QIAGENは、LRRK2阻害剤に対するパーキンソン病の反応性を予測する、Neuron23が発見したバイオマーカーの混合物を検出する臨床試験アッセイの設計と検証を行います。さらに、この提携は、現在前臨床開発の後期にあるNeuron23社の医薬品候補の臨床開発を支援するものです。さらに、臨床開発の進展に応じて、コンパニオン診断薬を追加で開発するオプションも盛り込まれています。

予測診断テストに関する専門知識の不足が市場成長の妨げとなる

しかし、慢性変性疾患を特定するためのバイオマーカーの信頼性は低く、予測診断テストにおける専門知識の欠如が、予測期間中の市場の抑制要因となります。

COVID-19の影響分析

COVID-19の登場は、世界の予知診断市場にポジティブな影響を与えました。Advances in Biomarker Sciences and Technology in 2020に掲載された記事によると、バイオマーカーは、特にワクチンの分野において、新しい革新的な医薬品や生物学的製品の開発および承認を強化できるため、パンデミック状態において特に重要であるとされています。バイオマーカーは、特定の疾病の観察可能な特徴を記述し、その表現型や遺伝子型に基づいて最適な治療法を決定するために応用できるため、非常に注目されています。特に、急性呼吸窮迫症候群（ARDS）などの呼吸器系疾患のバイオマーカーは、死亡率の上昇（IL-8、ICAM-1）および生存率の向上（一酸化窒素）に関連していることが分かっています。これらのバイオマーカーは、将来の合併症や疾患の重症度を予測する上で極めて重要な役割を担っており、COVID-19の予後の指標として有用である可能性があります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 慢性疾患の有病率の上昇
      • 様々な種類のがんの増加
      • 様々な遺伝子疾患の早期発見の必要性
    • 抑制要因
      • バイオマーカーの信頼性が低い
      • 専門知識の不足
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 タイプ別

  • 前駆症状型
  • 前駆症状型

第8章 アプリケーション別

  • 循環器系疾患
  • 神経系疾患
  • 遺伝性疾患
  • がん領域
  • その他

第9章 エンドユーザー別

  • 診断薬
  • 遺伝子検査機関・クリニック
  • 研究・学術機関

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • タイプ別ベンチマーク

第12章 企業プロファイル

  • Abbott Molecular
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Almac Group Ltd.
  • Ambry Genetics Corporation
  • BioGenex
  • Epistem Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • MDxHEALTH, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Prometheus Laboratories Inc.
  • Proteomics International Laboratories Ltd
  • QIAGEN N.V.

第13章 予測診断の世界市場-DataM

目次
Product Code: DMCD1123

Market Overview

The Global "Predictive Diagnostics Market" size was valued at US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, Predictive diagnostics can assist deliver impactful and measurable advancements to operations.

Market Dynamics

The global predictive diagnostics market is driven by technological advancements, growing adoption of predictive diagnostics in research and development, rising lifestyle disease, and an increasingly health-conscious population.

Increasing benefits of predictive diagnostics in healthcare drives market growth

The technological advancements in diagnostics sectors drive the market in the forecast period. According to the Philips report, June 2020, predictive analytics in healthcare help detect early signs of patient degeneration in intensive care units and general wards, recognize at-risk patients in their residences to prevent hospital readmissions, and prevent avoidable downtime of medical equipment. Predictive diagnostics allows combining data from multiple sources - including hospital-based electronic medical records, fall detection pendants, and the historical use of medical alert services - to identify seniors at risk of emergency transport in the next 30 days. Predictive diagnostics allows healthcare providers to reach out to a senior person before a fall or another medical complication occurs, preventing unnecessary hospital readmissions and reducing transportation, acute care, and rehabilitation costs.

In addition, the market players are applying the market strategies such as product launches and collaboration to expand their business. For instance, in October 2021, bioMerieux - a French multinational biotechnology firm focusing on in-vitro diagnostics - launched predictive Diagnostics, the company's new offering in food safety and food quality. Also, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease. In this agreement, QIAGEN will design and validate a clinical trial assay that will detect a mixture of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to an LRRK2 inhibitor. Furthermore, this partnership will support the clinical development of Neuron23's drug candidate, which is presently in the late stages of preclinical development. Subject to further clinical development, the agreement also enfolds options for developing additional companion diagnostics.

The lack of expertise in predictive diagnostics testing will hamper the growth of the market

However, less reliability of biomarkers for identifying chronic degenerative diseases and lack of expertise in predictive diagnostics testing will restrain the market in the forecast period.

COVID-19 Impact Analysis

The appearance of COVID-19 positively impacted the global predictive diagnostics market. As per the article published in Advances in Biomarker Sciences and Technology in 2020, biomarkers are particularly important during a pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Biomarkers can be applied to describe observable characteristics of certain diseases and determine optimal treatments based on these phenotypes and genotypes; thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide). These biomarkers play a pivotal role in predicting future complications or disease severity and could be useful as an indicator for COVID-19 prognosis.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most familiar cancers are breast, colon, lung, rectum, and prostate. Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

As per the article published in Frontiers in Oncology in September 2022, predictive biomarkers in the context of progressive disease treated with chemotherapy are also included. A meta-analysis of clinicopathological features that predict necrosis/fibrosis in retroperitoneal residual masses of non-seminoma patients, including histopathological features in the orchiectomy specimen (absence of teratoma, presence of seminoma), as well as serum tumor markers (normal HCG and AFP, elevated LDH) and size of the mass (>50% change in size, smaller residual mass size). A

Also, identified features that predict the development of choriocarcinoma syndrome (a severe complication, challenging to treat and with considerable mortality) in poor-risk germ cell tumor patients, including metastatic lung involvement of more than half and ECOG PS around two. Rising cancer cases and demand for predictive diagnostics drives the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global predictive diagnostics market

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. The market is driven by improved healthcare infrastructure, the increasing incidence of infectious disease, active regional key players, and easy availability of products in the region.

The market players are offering predictive diagnostics in the North American region. For instance, F. Hoffmann-La Roche Ltd provides predictive diagnostics solutions for oncology, cardiovascular disease, infectious disease, respiratory disease, autoimmune disease and more.

In addition, key players are adopting the market strategies such as acquisition and product launches. For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases.

Competitive Landscape

The predictive diagnostics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc, Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the predictive diagnostics market globally.

For instance,

In September 2021, Janssen-a pharmaceutical subsidiary of Johnson & Johnson - introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatments and therapies.

QIAGEN

Overview:

QIAGEN is a German organization founded in 1984 and headquartered in Hilden, Germany. It delivers the solutions for molecular testing and provides the answer from the building blocks of life- DNA, RNA, and protein to the customers to unblock the new insights.

Product Portfolio:

NextSeq 550Dx: This instrument is FDA-regulated and CE-in vitro diagnostic (IVD) marked, allowing clinical laboratories to design and execute a broad range of applications, from Next Generations sequencing solutions IVD assays using targeted panels to clinical research applications that include techniques from targeted panels to whole genomes.

The global predictive diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in prevalence of chronic diseases
      • 4.1.1.2. Increasing prevalence in various types of cancer
      • 4.1.1.3. Need for detection of various genetic disorders at the earliest stage
    • 4.1.2. Restraints:
      • 4.1.2.1. Less reliability of biomarkers
      • 4.1.2.2. Lack of expertise
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Presymptomatic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Predispositional

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurological Diseases
  • 8.4. Genetic Diseases
  • 8.5. Oncology
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Genetic Laboratories and Clinics
  • 9.4. Research and Academic Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Type Benchmarking

12. Company Profiles

  • 12.1. Abbott Molecular*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Almac Group Ltd.
  • 12.3. Ambry Genetics Corporation
  • 12.4. BioGenex
  • 12.5. Epistem Ltd.
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Genomic Health, Inc.
  • 12.8. MDxHEALTH, Inc.
  • 12.9. Myriad Genetics, Inc.
  • 12.10. OPKO Health, Inc.
  • 12.11. Prometheus Laboratories Inc.
  • 12.12. Proteomics International Laboratories Ltd
  • 12.13. QIAGEN N.V.

LIST NOT EXHAUSTIVE

13. Global Predictive Diagnostics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us